drugset / Trial / NCT01423240

Major Depressive Disorder With Mixed Features

NCT01423240

Phase 3 Withdrawn Sumitomo Pharma America, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.

Timeline

Start
2012-01
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 20 mg Oral
Subject Lurasidone Small molecule 60 mg Oral